Press Releases

-U.S. FDA has issued a clinical hold on Phase 1/2 Clinical Trial of SEL-302 due to CMC related questions- WATERTOWN, Mass. , Nov. 24, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop

WATERTOWN, Mass. , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management

-Established four strategic collaborations to advance next generation therapeutics and maximize the potential of ImmTOR platform- -Reported topline data from SEL-399 (empty AAV8 capsid in combination with ImmTOR); Selecta intends continued expansion of ImmTOR platform across gene therapy pipeline-

- At day 30, of subjects in the 0.3mg/kg ImmTOR cohort, 100% showed NAb titers of ≤ 1:25, and 67% showed NAb titers of ≤ 1:5 - - With co-administration of AAV8 empty capsids and ImmTOR, Selecta observed dose-dependent response to ImmTOR with a safety profile in line with prior human studies - -

WATERTOWN, Mass. , Nov. 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it plans to host a

Leveraging Ginkgo’s cell programming platform and Selecta’s ImmTOR platform to create potentially transformative enzymatic therapies Selecta gains rights to develop and commercialize select therapeutic enzymes from Ginkgo’s advanced organism engineering platform to treat select auto-immune diseases

- Selecta obtains from Genovis exclusive worldwide rights to Xork, a differentiated IgG protease - - Selecta combines ImmTOR ™ platform with Genovis’ novel IgG protease, Xork, to unlock the full potential of transformative gene therapies and treat certain IgG-mediated autoimmune diseases - - This

WATERTOWN, Mass. , Oct. 20, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management

WATERTOWN, Mass. , Oct. 13, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced it will be presenting

Selecta’s ImmTOR™ platform enhances transgene expression and addresses adeno-associated virus (AAV) vector immunogenicity constraints to deliver transformative therapies WATERTOWN, Mass. , Oct. 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging